BCL2L1 and colorectal carcinoma: Furthermore, since CRC cells are dependent on BCL-xL, but normal intestinal stem cells are not, the highly potent and selective BCL-xL inhibitor A-1155463 (BCLi) may selectively kill tumor cells [22].